Thanks to our readers who dive into it all — from experimental immunotherapy to cancer immunobiology to innovative methods 💙 You prove that science is stronger when we stay curious, stay current, and stay connected. #CancerCure #ResearchMatters

For those who couldn't attend the new #AACRIO25 meeting, check out our digest here 👉 bit.ly/3XvBUkp. We included talks from @jimallisonphd.bsky.social, @danielathommen.bsky.social, @jcstark.bsky.social#AACRIO25and more! (1/2)

Tailored cancer vaccine combined with PD-1 blockade in phase 1 trial  @drcamidge.bsky.social bit.ly/40CHemx #immunoSky

Mok et al. evaluated the differences in memory responses between anti-CTLA-4 and anti-PD-1 to better understand why responses to anti-CTLA-4 last longer bit.ly/42oLGrD  @mdanderson.bsky.social  @jimallisonphd.bsky.social

Anti-TIGIT and anti-PD-L1 work together to support the generation of new antigen-specific T cells in dLNs, which then migrate to the blood, seed tumors, and help to mediate strong antitumor immunity bit.ly/3CcaM2d

A tetraspecific NK cell engager armed with IL-2v tops T cell engagers against B-NHL in preclinical studies 👉 acir.org/weekly-dige...

Sectarianism in immunology. (highly specific for immunologists, all credit to @pedromics on X) 1/8

Here’s our comprehensive roundup of the most impactful research and key insights from the SITC Annual Meeting 2024. acir.org/weekly-diges...

To my friends and colleagues exploring career options in Europe

Missed the AACR Tumor Immunology and Immunotherapy Meeting 2024 in Boston? Check out our special feature highlighting key talks and breakthroughs from the event acir.org/weekly-diges...